Abiomed,
Inc. (NASDAQ: ABMD) announced today that on Thursday, August 6,
2009, the Company will release financial results for the first quarter
of fiscal 2010. The...
biomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today announced its forecast for fiscal 2010
revenue growth to be in the range...
#55: ABMD Stock News : FDA Approves Abiomed’s New AB Portable™ Driver; Providing Patient Transport, Mobility and Ambulation without Compromising Performance
Abiomed
Inc. (NASDAQ: ABMD), a leading provider of heart recovery products
designed to recover hearts and eliminate in-hospital deaths from heart
attacks and high...
Abiomed, Inc. (NASDAQ: ABMD) announced today that Michael R. Minogue,
Chairman, President and Chief Executive Officer, will present at the
2008 Morgan Stanley Global Healthcare...
Abiomed Announces Update on 510(k) Clearance Process for Impella 2.5 Circulatory Support Device
Abiomed, Inc. (NASDAQ: ABMD) today announced an update on the 510(k)
clearance...
CMS Proposes Coverage with Evidence Development (CED) Decision
Abiomed Inc. (NASDAQ: ABMD) recently received a proposed National
Coverage Decision (NCD) from the...
Three of Four FDA Questions on 510(k) Submission Now Resolved, Only
Bench Testing Pending
Abiomed, Inc. (NASDAQ: ABMD) today announced it recently received a...
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of medical devices that provide circulatory support to acute heart failure patients today announced a strategic investment in WorldHeart...
- Provides for Collaboration on Marketing and Clinical Support -
OAKLAND, Calif., Dec. 12 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX: WHT) -- World Heart Corporation (WorldHeart or the...
Abiomed, Inc. (NASDAQ: ABMD) today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will participate on the "Matters of the Heart: Bringing Innovation...
Abiomed, Inc. (NASDAQ: ABMD) announced today that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Piper Jaffray Annual Healthcare Conference on...
Revenue up 5% to $11.4 million
Impella 2.5 High-Risk PCI Pivotal Trial Conditionally Approved in Late Fiscal Q2 2008
Customer Orders of $1.6 million for Impella 2.5 Pivotal Trial...
Abiomed, Inc. (NASDAQ: ABMD) announced today that on Thursday, November 8, 2007, the Company will release second fiscal quarter 2008 results. The Company will host a conference call to...